Aby Mathew Sells 529 Shares of BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby Mathew sold 529 shares of BioLife Solutions stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $20.74, for a total value of $10,971.46. Following the completion of the transaction, the executive vice president owned 392,937 shares in the company, valued at approximately $8,149,513.38. This represents a 0.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

BioLife Solutions Trading Down 1.3%

Shares of NASDAQ BLFS opened at $19.86 on Friday. The company has a market cap of $959.24 million, a price-to-earnings ratio of -180.53 and a beta of 1.90. BioLife Solutions, Inc. has a 12 month low of $19.10 and a 12 month high of $29.62. The stock has a 50-day moving average price of $23.37 and a two-hundred day moving average price of $25.07.

Hedge Funds Weigh In On BioLife Solutions

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. acquired a new stake in BioLife Solutions during the 1st quarter valued at approximately $283,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of BioLife Solutions by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,422 shares of the medical equipment provider’s stock worth $489,000 after purchasing an additional 914 shares during the period. Jane Street Group LLC bought a new stake in shares of BioLife Solutions in the 1st quarter valued at $1,091,000. Strs Ohio bought a new stake in shares of BioLife Solutions in the 1st quarter valued at $153,000. Finally, Vestmark Advisory Solutions Inc. increased its position in shares of BioLife Solutions by 160.3% during the second quarter. Vestmark Advisory Solutions Inc. now owns 24,438 shares of the medical equipment provider’s stock worth $526,000 after buying an additional 15,049 shares during the period. 93.24% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about BioLife Solutions

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: Analyst/preview: Seeking Alpha highlights BioLife’s strategic refocus on core biopreservation media and vials, forecasting ~17–20% revenue growth in FY2026, positive GAAP net income and mid‑60s gross margins; cites the PanTHERA acquisition and a QKine partnership as drivers of higher ARPU and next‑gen product launches by late‑2026. BioLife Looks Strong For Fiscal Year 2026
• Positive Sentiment: Company presentation/press release: BioLife reiterated its growth and strategic refocus in a recent presentation, reinforcing management’s turnaround narrative and the FY26 outlook that underpins the Seeking Alpha preview. BioLife Solutions Highlights Growth and Strategic Refocus in Presentation
• Neutral Sentiment: Short‑interest data published for early March shows zero shares / 0.0 days‑to‑cover — this appears erroneous or non‑informative and does not indicate material short pressure at present. MarketBeat BLFS
• Negative Sentiment: Insider selling: Multiple senior executives (CFO, CMO, EVP, CTO and others) disclosed modest open‑market sales (hundreds of shares apiece at ≈$20.74). Amounts are small relative to their holdings, but clustered sales can trigger short‑term headline risk and investor caution. Insider trading alert

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, January 21st. Wall Street Zen raised shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of BioLife Solutions in a report on Monday, December 29th. UBS Group reiterated a “buy” rating on shares of BioLife Solutions in a research note on Monday, December 29th. Finally, Northland Securities set a $34.00 price objective on BioLife Solutions in a report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.